Characteristics and Outcomes of Patients Receiving Volatile Anesthetics in Near-Fatal Asthma: A Retrospective Observational Cohort Study
Open Access
- 30 July 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Explorations
- Vol. 7 (8) , e1295
Abstract
IMPORTANCE AND OBJECTIVES: Inhaled volatile anesthetics are employed as rescue therapy in near-fatal asthma, despite limited evidence. This study aims to describe the characteristics, management, and outcomes of mechanically ventilated adult patients with near-fatal asthma, stratified by the use of volatile anesthetic therapy. DESIGN: Retrospective single-center observational cohort study. SETTING: Tertiary critical care and extracorporeal membrane oxygenation (ECMO) unit. PARTICIPANTS: Adults 16 years old or older receiving mechanical ventilation (MV) for greater than or equal to 24 hours and/or ECMO between January 2016 and August 2023 for near-fatal asthma. MAIN OUTCOMES AND MEASURES: We recorded demographics, disease severity tidal volumes, and ventilator settings, by treatment over the first 100 hours. Outcomes were duration of ECMO and MV, ICU length of stay, 90-day mortality, and adverse drug reaction. RESULTS: Sixty-two patients were included (62.9% female), with a median (interquartile range [IQR]) age of 45 years (29–51 yr). Median (IQR) pH 7.13 (6.93–7.23), Paco 2 12.9 kPa (8.7–16.2 kPa), and tidal volume 178 mL (50–300 mL). Most patients received IV bronchodilators and 32 (51.6%) required ECMO. Thirty-eight patients (61.3%) were treated with volatile anesthetics. Volatile patients had worse ventilation and blood gas parameters before treatment, more barotrauma, and were more likely to be receiving ECMO. Despite this, improvements in tidal volume occurred in the volatile group (mean increase, 204 mL [83.9%]; 95% CI, 110–298; p < 0.001). Median (IQR) duration of MV and ICU length of stay in volatile and no volatile patients were 10 days (8–16 d) vs. 5 days (3–10 d; p = 0.001) and 15 days (13–20 d) vs. 9 days (7–14 d; p = 0.001), respectively. ICU and 90-day mortality in volatile and no volatile patients were 5.3% vs. 4.2%. CONCLUSIONS AND RELEVANCE: The use of inhaled volatile anesthetics for near-fatal asthma, including during ECMO, appears to be feasible and safe, and with favorable clinical outcomes; however, no conclusions regarding efficacy can be directly inferred.Keywords
This publication has 35 references indexed in Scilit:
- Inhaled Sedation in Acute Respiratory Distress SyndromeJAMA, 2025
- Clinical use and safety of volatile anaesthetic sedation in mechanically ventilated adult patients: a retrospective single-centre cohort studyBritish Journal of Anaesthesia, 2024
- Avoiding kidney damage in ICU sedation with sevoflurane: use isoflurane insteadBritish Journal of Anaesthesia, 2022
- Comparison of isoflurane and propofol sedation in critically ill COVID-19 patients—a retrospective chart reviewJournal of Anesthesia, 2021
- Nephrogenic diabetes insipidus associated with prolonged sedation with sevoflurane in the intensive care unitBritish Journal of Anaesthesia, 2019
- Sevoflurane therapy for life-threatening acute severe asthma: a case reportCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 2014
- Definition of Critical Asthma SyndromesClinical Reviews in Allergy & Immunology, 2013
- The Critically Ill Asthmatic—from ICU to DischargeClinical Reviews in Allergy & Immunology, 2011
- Incidence, risk factors and outcome of barotrauma in mechanically ventilated patientsIntensive Care Medicine, 2004
- A comparison of sevoflurane with halothane, enflurane, and isoflurane on bronchoconstriction caused by histamineCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1994